AllDocs -> cancers

LYMPHOMA PCP. ELIGIBILITY CRITERIA INCLUSION CRITERIA: To be eligible for inclusion in this trial, all of the below boxes should be ticked. • Biopsy proven diagnosis of low grade non-Hodgkin’s lymphoma including the following histological subtypes: Follicular lymphoma , Follicular mixed small-cleaved and large cell, Diffuse small lymphocytic lymphoma , Lymphoplasmacytic lymphoma , Splenic marginal zone lymphoma , Extranodal marginal zone lymphoma of MALT type, Nodal marginal zone B-cell lymphoma Low grade B cell lymphoma not otherwise specified. • Previously untreated disease. • Able to undergo study procedures / treatment. • ECOG performance status grade < 2. • > 18 years of age. • Available for follow-up for a minimum of 12 months. • Able to provide informed consent. EXCLUSION CRITERIA: To be eligible for ...

Patho-Biology of Malignant Lymphoma at NCI Nadia Mokhtar, Ph.D. NCI, Cairo University Page 2 Prevalence of NHL: rank among all cancer types 5 th 5 th USA 3 rd 3 rd Egypt 11 th 10 th World FEMALES MALES REGION Page 3 Page 4 ML 10.1% Total Malignancy NHL HL 69.7% 30.3% Nodal 70.8% Extra Nodal 29.2% Cancer Pathology Registry 1998-2000 (n=1095) Lymphoma : Leukemia Ratio 1.2:1 Male: Female Ratio 2.5:1 Page 5 T 12% B88% Immunophenotyping Page 6 B ...

March 2004 Total registrations 46,624 New registrations 6915 (since EBMT 2002) Total number of centres 522 New centres 12 EBMT Lymphoma Registry Page 2 March 2004 Lymphoma transplants: by year of transplant 0 1000 2000 3000 4000 5000 6000 7000 8000 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002+ Year of transplant No. of transplants Page 3 March 2004 Lymphoma transplants: Classical vs reduced intensity conditioning 0 100 200 300 400 500 600 700 800 900 1000 <1995 1995 1996 1997 1998 1999 2000 2001 2002 2003+ Year ...

Page 2 Page 3 1 Acknowledgements Our thanks to Reta Johnstone and Catriona Gilmour Hamilton for putting this information together, mostly drawn from the Lymphoma Association’s booklets ‘Treatment choices in low grade follicular lymphoma ’ written by Professor John Sweetenham and ‘Lymphomas’ written by Catriona Gilmour Hamilton. Patients’ views and some of the quotations included here were taken from a questionnaire asking people what it is like to live with follicular lymphoma ; this was carried out by the Lymphoma Association in 2000. Thanks also go to our reviewers, Professors Martin Dyer and John Sweetenham, and Dr Robert Marcus; and to three individuals with personal experience of lymphoma , Keith and Aline Nowell and Lesley-Anne Robins. Sponsor With grateful thanks to GlaxoSmithKline for assistance with ...

The official online magazine of the Massachusetts Youth Soccer Association; April 2004 shop adidas.com Kicks for Cancer 2004 Young Referees of the Year KNVB Programs in the Boston Area Mass Youth Soccer Olympic Development Teams Announced TOPSoccer News Prevention of ACL Injuries Coach's Clipboard Soccer News Blurbs and Blips Approved Tournaments Referee Courses Mass Youth Soccer and Leukemia & Lymphoma Society Join Teams for the Fight Against Cancer Soccer Kicks for Cancer is a soccer development, community outreach and fundraising program developed by US Youth Soccer and The Leukemia & Lymphoma Society. Soccer players raise funds for research and patient programs by getting donations for the number of “touches” they make on the soccer ball at home over a ten day period. ...

The official online magazine of the Massachusetts Youth Soccer Association; May 2004 shop adidas.com ODP Mini Camp Mass Boys ODP Trip to Portugal High Performance Sports: Periodization Training Kicks for Cancer KNVB Programs in the Boston Area TOPSoccer - Share the Joy of Soccer! Coach's Clipboard Soccer News Blurbs and Blips Approved Tournaments Referee Courses Mass Youth Soccer and Leukemia & Lymphoma Society Join Teams for the Fight Against Cancer Soccer Kicks for Cancer is a soccer development, community outreach and fundraising program developed by US Youth Soccer and The Leukemia & Lymphoma Society. Soccer players raise funds for research and patient programs by getting donations for the number of “touches” they make on the soccer ball at home over a ten day period. ...

LYMPHOMA RESEARCH -FOUNDATION July 30, 2004 The Honorable Lester Crawford, D.V.M, Ph.D Acting Commissioner Food and Drug Administration Parklawn Building 5600 Fishers Lane Room 1471 Rockville, MD 20857 RE: Docket No. 2004-N-0181 Dear Dr. Crawford: The Lymphoma Research Foundation (LRF) is the nation’s largest lymphoma -focused voluntary health organization devoted exclusively to funding lymphoma research and providing patients and healthcare professionals with critical information on the disease. We appreciate the opportunity to comment on the report, “Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products,” and to offer recommendations to improve the development of new cancer therapies. We appreciate FDA’s effort to identify problems in the development of new therapies and to invite proposals from the public ...

Lymphoma : Non-Hodgkins Disease - Overview © copyright 2004 U-M Comprehensive Cancer Center The University of Michigan Health System web site does not provide specific medical advice and does not endorse any medical or professional service obtained through information provided on this site or any links to this site. Use of the UMHS web site does not replace medical consultation with a qualified health or medical professional to meet the health and medical needs of you or others. While the content of the UMHS web site is frequently updated, medical information changes rapidly and therefore, some information may be out of date, and/or contain inaccuracies or typographical errors. Lymphoma is the third most common cancer in children in the United States. Approximately 10 percent of cancers in children less than 15 years of age are lymphomas. Two broad categories of lymphoma are recognized -- ...

Published Quarterly Mangalore, S outh I ndia I SS N 0972-5997 Volume 3; I ssue 2; April - June 2004 Case Report Orbital MALT Lymphoma : A Case Report Shobha G Pai, MS, DOMS, Associate Professor* Sumana J Kamath, MS, Associate Professor* Manjunath M Kamath, MS, DOMS, Associate Professor* Aarthi R Rau, MD, Assistant Professor,** Jay Kumar Chhablani, MBBS, Postgraduate Student* *Dept. of Ophthalmology, Kasturba Medical College Hospital, Attavar, MANGALORE **Dept. of Pathology, Kasturba Medical College, MANGALORE Address for Correspondence: Dr. Shobha G Pai, MS, DOMS, Associate Professor, Dept. of Ophthalmology, Kasturba Medical College Hospital, Attavar, MANGALORE, INDIA. Pin: 575001 E-mail: drsgpai@rediff.com Citation: Pai SG, Kamath SJ, Kamath MM, Rau AR, Chhablani JK. Orbital MALT Lymphoma : A Case Report. Online J Health Allied ...

1. The Glycobiology Institute, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, U.K. 2. Molecular Immunology Group, Tenovus Laboratory, Cancer Sciences Division, Southampton University Hospitals Trust, Southampton SO16 6YD, UK. 3. Clinical Universitaria de Navarra, University of Navarra, 31003, Pamplona, Spain. A potential survival strategy for human follicular lymphoma cells involving oligomannose glycans in the antigen binding site of IgG Radcliffe, C.M. 1 , Arnold, J.N. 1 , Suter, D.M. 1 , Wormald, M.R. 1 , Harvey, D.J. 1 , Bendandi, M. 3 , Dwek, R.A. 1 , Stevenson, F.K. 2 Rudd, P.M. 1 INTRODUCTION : FL cells express a strikingly high incidence of glycosylation sites in the variable regions of their surface immunoglobulins (Igs), a feature ...

About Non-Hodgkin’s Lymphoma About 54,370 new cases of non-Hodgkin lymphoma (NHL) will occur this year in the United States. Lymphomas are cancers that begin by the malignant transformation of a lymphocyte in the lymphatic system. The prefix "lymph" indicates their origin in the malignant change of a lymphocyte and the suffix "oma" is derived from the Greek word meaning "tumor". Lymphomas, including Hodgkin lymphoma , result from an acquired injury to the DNA of a lymphocyte. Scientists know that the damage to the DNA occurs after birth and, therefore, is acquired rather than inherited. The change or mutation of DNA in one lymphocyte produces a malignant transformation. This mutation results in the uncontrolled and excessive growth of the lymphocyte, and confers a survival advantage on the malignant lymphocyte and the cells that are formed from its multiplication. The accumulation of these dividing cells results in ...

MDACC Diffuse Large B-Cell Lymphoma a (Page 1 of 5) (V1; 8/8/03) No No Note: If available, clinical trials should be considered as preferred treatment options for eligible patients. Yes Yes No Yes Low Risk High Risk PATHOLOGIC DIAGNOSIS INITIAL EVALUATION Hematopathology review of all slides with at least one paraffin block representative of the tumor. Rebiopsy if consult material is nondiagnostic. Adequate immunophenotyping to establish diagnosis b > Paraffin panel: CD45 (LCA),CD20 (26/Pan B), CD3;(optional - cytokeratin) or > Cell surface marker analysis by flow cytometry: kappa/lambda, CD45, CD3, CD5, CD19, CD10, TdT, CD14, CD13, CD33, CD20 Additional immunohistochemical studies to establish lymphoma subtype > ...

(Page 1 of 1) CLINICAL STAGE LOCAL TREATMENT (V1; 9/26/03) No No Note: If available, clinical trials should be considered as preferred treatment options for eligible patients. Yes Yes No Yes Low Risk High Risk Non-Gastric MALT a Lymphoma Stage IE - II Clinical Trial or Locoregional Radiotherapy with or without Rituxan Surgery for certain sites (lung, breast [with or without Radiotherapy], skin c , thyroid, colon/small bowel) Stage III - IV low grade Stage IE - IV, MALT a lymphomas coexistent with large cell lymphoma b Treat per Diffuse Large B-Cell Lymphoma Guidelines (Page 1) a MALT = mucosal - associated lymphoid tissue. b DLBCL coexistent with MALT cell lymphoma is ...

Hodgkin's Lymphoma (Page 1 of 11) (Draft 2 5/22/03) Draft 3 6/3/03 DRAFT 8/5/03 D evelopment C redits DIAGNOSIS WORKUP History and physical including: -B symptoms -ETOH intolerance -Pruritus -Fatigue -Performance status -Exam of nodes -Spleen, liver CBC, differential, platelets LDH, Liver Function Tests including Alkaline phosphatase, SGOT, SGPT, and albumin, BUN, creatinine Beta-2-microglobulin HIV 1 and HIV 2 Chest X-ray CT Neck, chest, abdomen and pelvis PET or gallium scan especially if equivocal CT Bilateral bone marrow biopsies Pulmonary function studies if clinically indicated MUGA or echocardiogram Counseling: Fertility, psychosocial if clinically indicated FNA alone is generally insufficient Core needle biopsy may be adequate if diagnostic, but recommend ...

CATIE Fact SHEET Lymphoma , page 1 of 3 Fact SHEET LYMPHOMA What is lymphoma ? Lymphoma is a term used to described several different cancers that can affect the lymphatic system. In HIV-positive people, lymphoma is linked to immune deficiency. The risk of developing lymphoma seems to increase as the immune system weakens. There are two general types of lymphomas: Hodgkin’s disease and non-Hodgkin’s lymphoma (NHL). Although both types can affect people living with HIV, NHL is classified as an AIDS-defining illness. Lymphoma originates in a type of white blood cell called a B-cell. These cells may start to grow rapidly and develop into tumours that can spread in the lymphatic system. The lymphatic system is made up of vessels that branch out into all parts of the body. These vessels carry lymph, a clear, watery fluid that contains the ...

1 MEET THE EXPERT ON NON-HODGKIN LYMPHOMA : N EW I NSIGHTS AND T REATMENTS LLS 04-05 Sullivan 6/10/04 MR. SULLIVAN: My name is Larry Sullivan. I was diagnosed with non-Hodgkin lymphoma approximately 3 years ago. It was discovered by myself while shaving. I felt a lump, went to the doctor, had a fine-needle biopsy, CAT scans, and it was identified as indolent non-Hodgkin lymphoma . The treatment options presented to me at the time were to do nothing, just watch and wait, or to actively pursue the disease. I chose with my doctor to pursue it, and the options that were made available to me were radiation or Rituxan ® (Rituximab), which was emphasized, and that is the one that we chose. At that time, I had two enlarged lymph nodes that were identified, and both of them were removed and proved to be non-Hodgkin ...

Expression ofMAdCAM-1andPNAdin Inflamma toryand MALT Lymphoma Tissues of Ocular Adnexa, Thyroid, SalivaryGland and Lung - Yi-XuanLiu,NobuyaOhara,TadashiYoshino,Gui-ShanJinandTadaatsuAkagi Mucosa-associatedlymphoidtissue(MALT)lymphomasusuallyarisefromacquiredMALT induced bychronic inflammation or autoimmuneprocesses. In MALT ofthegastrointestinal tract lymphocyte homing mechanisms operate primarily through interactions between integrin, expressed on mucosal lymphocytes, and MAdCAM-1, expressed on endothelium of high endothelial venules (HEV). In the present study,theexpression ofMAdCAM-1andperipherallymphnodevascularaddressin(PNAd)was examined immunohistochemicallyin normal,inflamed and MALT lymphoma tissues ofvarious organs. It was shown that MAdCAM-1was expressed on HEV in thegastrointestinaltract and thyroid that are inflamed or affected with MALT lymphomas,but not in theocularadnexa,lung,and salivarygland. ...

Sara Kaiser Biochem 118 June 1, 2004 Non-Hodgkin’s Lymphoma Non-Hodgkin’s Lymphoma is currently the fifth most common cancer in the United States. For reasons as yet undetermined by scientists, it has become increasingly more common over the last several decades. Fortunately, the future of Non-Hodgkin’s Lymphoma looks to be promising, as research for new treatments has proved fruitful in the last decade. Lymphoma refers to cancer of the lymphatic system, and is broken up into two types: Hodgkin’s and Non-Hodgkin’s. Hodgkin’s disease is identified by “specific cells - Reed-Sternberg cells - that are not found in any other cancerous lymphomas or cancers” (NHL 1 )Both of these diseases involve a mutation among B lymphocytes – a type of white blood cell - which causes them to divide much more rapidly than normal cells. Unfortunately, it is not currently known what causes this mutation, ...

500 MJA Vol 177 4 November 2002 NOTABLE CASES The Medical Journal of Australia ISSN: 0025-729X 4 November 2002 177 9 500-501 ©The Medical Journal of Australia 2002 www.mja.com.au Notable Cases A 63-year-old man with rheumatoid arthritis presented with pain and swelling of his right buttock. Imaging and tissue biopsy revealed a diffuse large B-cell, non-Hodgkin’s lymphoma . The disease- modifying drugs he was taking, cyclosporin and methotrexate, were stopped, and the lymphoma resolved spontaneously without the use of chemotherapy. (MJA 2002; 177: 500-507) R HEUMATOID ARTHRITIS is a common disorder. Its various articular and extra-articular manifestations are well described, but less well known is the association between rheumatoid arthritis and malignancy. There is an intrinsic risk of lymphoma , particularly non-Hodgkin’s lymphoma ...

Case Report Ind. J. Tub. 2000, 47, 107 LYMPHOMA OF SPINE PRESENTING AS POTT’S DISEASE : A CASE REPORT Veena Maheshwari 1 , Kiran Alam 2 , Shah Aiam Khan 3 *, Ghazala Mehdi 2 and A.A. Iraqi 4 * (Original version received on 16.9.99; Revised version received on 15.1.2000; Accepted on 29.2.2000) Summary: A rare case of primary non-Hodgkin’s lymphoma of spine in a 40 year old female, initially diagnosed and treated as Pott’s disease is presented. INTRODUCTION Lymphomas and leukemias rarely involve the vertebral column. The clinical manifestations of lymphoma can closely mimic tuberculous spondylitis 1 . Lymphoma of bone is usually secondary to lymphoma of lymphoid tissue. CASE REPORT A 40 year old female presented with pain ...

Intra-Arterial Chemotherapy for CNS Lymphoma Intra-Arterial Chemotherapy Treatment Schedule: • Intra-arterial chemotherapy requires a hospital stay for 2 nights after the first treatment. You will be discharged on the 3 day between 9:00 and 10:00 in the morning. You will be rd discharged the 2 day after subsequent treatments are completed. nd • You will be scheduled for admission to the hospital every 4-5 weeks. After every 2 cycles of chemotherapy, a MRI will be done to see how effective the treatment was on the tumor. Dr. Newton will go over the MRI scans with you. If your MRI is done at another facility, please bring to your doctor’s appointment the old and new scan for comparison. If your MRI is done at OSU, please bring all the films with you to see Dr. Newton. The MRI department should send them with you. • On the day of admission, please report to The James Cancer ...

252 Korean J Radiol 4(4), December 2003 Primary Calcified T-Cell Lymphoma of the Urinary Bladder: A Case Report Primary malignant lymphoma of the urinary bladder is extremely rare, and to our knowledge, no case described in the radiologic literature has been accompa- nied by calcification. We report a case in which the condition was associated with calcification, and describe the pelvic CT and MR imaging findings. rimary lymphoma of the urinary bladder accounts for less than 1% of the neoplasms occurring in this organ. A few cases have been reported in the radiology literatures (1 3), but in no instance has been described associ- ated calcification. We report the CT and MR imaging findings in a patient with urinary bladder lymphoma involving internal calcification. CASE REPORT A 30-year-old woman presented with a two-month history of gross hematuria and dysuria. ...

Lymphoma - page 1 LYMPHOMA Lecture date 2004 Mar 31 Course Meds 412 - Phase 2A Lecturer Dr. David Lee Notes updated 2004 Feb 28 W HAT ARE LYMPHOMAS ? Lymphomas are B- and T-cell neoplasms that typically result in the enlargement of lymph nodes; however, the spleen, bone marrow and other tissues may also be infiltrated. L YMPH OMA VS L EUKEMIA In general, those neoplasms which predominantly affect lymph nodes or tissues are referred to as lymphomas, and those affecting the bone marrow with circulating neoplastic cells in the blood as leukemias. This distinction is both fuzzy and somewhat artificial because any lymphoid neoplasm can have both solid and circulating components to them. C ONCEPTUALIZING LYMPHOID NEOPLASMS AS EXPANSIONS OF DEVELOPMENTAL STAGES IN LYM PHOPOIESIS ...

SPRING 2004 VOLUME 3 NUMBER 1 Lymphoma Today LRF Announces $1,065,000 in New Research Awards Passing The Torch of LRF Leadership The highest priority of the research program of the Lymphoma Research Foundation (LRF) is to support and encourage the efforts of top fellows and scientists at the nation’s lead- ing academic institutions to expand their research efforts and accelerate the process of developing successful treatments and ultimately a cure for lymphoma . John M. Pagel, MD, PhD; of the Fred Hutchinson Cancer Research Center in Seattle, WA will receive $ 225,000 in total for his project titled Pretargeted Radioimmunotherapy for CD20+ Non-Hodgkin’s Lymphoma . The overall objective of this project is to improve the efficacy and decrease the toxicity of radioimmunotherapy for patients with relapsed non- Hodgkin’s lymphomas by dramatically improving the ratio of radiation ...

. Your Treatment Team Your Treatment Team LEADING THE SEARCH FOR A CANCER CURE Sylvester Comprehensive Cancer Center 1475 NW 12th Avenue • Miami, Florida 33136 305-243-1000 1-800-545-2292 www.sylvester.org An Equal Opportunity/Affirmative Action University . Leukemia, Lymphoma , and Myeloma UM/Sylvester’s leukemia, lymphoma , and myeloma treatment team includes highly trained hematologist/oncologists and radiation oncologists, all widely recognized for their work in the field. The team is supported by a group of basic science and clinical researchers who work diligently to learn more about these diseases—their detection and treatment, as well as options to improve each patient’s quality of life. As is true with all cancer specialties at UM/Sylvester, the blood-related ...

IMMUNOBIOLOGY The growth of cutaneousT-cell lymphoma is stimulated by immature dendritic cells Carole L. Berger, Douglas Hanlon, Daniel Kanada, Madhav Dhodapkar, Vivian Lombillo, Nianci Wang, Inger Christensen, Gregory Howe, Jill Crouch, Paul El-Fishawy, and Richard Edelson In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating CTCL cells are concentrated in the epidermis in close association with an immature den- dritic cell (DC), the Langerhans cell. Be- cause long-term in vitro culture of CTCL cells has proven difficult, the in vivo association with the major antigen-pre- senting cell (APC) of the epidermis has been postulated to play a role in directly stimulating the clonal T-cell proliferation. We report that CTCL cells can be repro- ducibly grown in culture for 3 months when cocultured with immature DCs. CTCLcells retain ...

Patients Against Lymphoma Patients helping Patients 1305 Mason Avenue Staten Island, NY 10306 Phone: 718-980-0635 | Fax: 801-409-5736 KarlS@Lymphomation.org www.Lymphomation.org W e are guided by our scientific advisors, the peer-reviewed literature, medical professionals fighting lymphoma , and patient questions . We continuously improve our website in response to visitor questions and patient needs . by linking you directly to reputable sources of information, such as ClinicalTrials.gov. Visit us at www.Lymphomation.org What’s Lymphoma ? L ymphoma is a cancer that affects blood cells called lymphocytes – immune cells that normally protect you from illness. Damage to genes in these cells can sometimes lead to abnormal cell behavior which makes ...

LEUKEMIA and LYMPHOMA TESTS FOR LAB USE ONLY: Date Received: Center For Human Genetics, Inc. Sample Type:_ Boston University School of Medicine Time: _ 700 Albany Street, Suite 408, Boston, MA 02118-2394 Lab No.: __ Director: Aubrey Milunsky, M.D., D.Sc. Telephone: (617) 638-7083, Fax: (617) 638-7092 PATIENT: NAME: Male DOB: ADDRESS: PHONE:(day) Female (eve) PHYSICIAN: NAME: PHONE: ADDRESS: FAX: E-MAIL: (Check all that Apply) Disease Probe Location or rearrangement CML: bcr-M (major) breakpoint bcr/abl t(9;22)(q34;q11.2) CM and ALL, bcr-M and bcr-m (minor) break-points bcr/abl-ES t(9;22)(q34;q11.2) M3 AML and M3 AML variant PML/RARA t(15;17)(q22;q21) M2 AML AML1/ETO t(8;21)(q22;q22) M4 and M4Eo AML, Rarely in M2 or M5 AML ...

Unusual caseof cutaneous T-cell lymphoma with a prominent reactivepopulation of B lymphocytes Yoshihiro Nozawa ,Kazuhiro Tasaki ,Mikio Ohtsuka ,Keiji Iwatuki , Kunihiko Tominaga and Masafumi Abe Department ofPathology Department ofDermatology,School ofMedicine,Fukushima Medical University,Fukushima,Japan. Surgical PathologyDivision,Takeda General Hospital,Aizuwakamatu,Japan A 58-year-old Japanese woman presented an eruption in the region of the back and the upper extremities, a subcutaneous nodule on the right breast, and a left cervical lymphadenopathy. The excision biopsy specimens, of a subcutaneous nodule and a lymph node, showed a vaguely nodular growth pattern comprising a smallCD20 IgD lymphocyteinfiltratearoundclustersofmedium-sizedor largeCD3 lymphoid cells,in which histologicaldistinction between malignant lymphoma and reactive lymphoidhyperplasiawasdifficult. Southern-blotanalysisrev...

Spectrum of Malignant Lymphoma in Sarawak General Hospital Suat-Cheng Peh ,HenryR Gudum ,Yan-Chin Tai , Fei-Ling Wong and Jamil Dolkadir Departments ofPathology,UniversityofMalaya,Kuala Lumpur UniversityofMalaysia,Sarawak Departments ofPathology,UniversityofMalaya,Kuala Lumpur Departments ofPathology,UniversityofMalaya,Kuala Lumpur Sarawak General Hospital,Kuching,Malaysia Recent epidemiological studies reported changing trend of lymphoid neoplasia in the past few decades. Previous studyoflymphomas from East Malaysia from 1981to 1983showed a pattern similar to other Asian countries,except for low incidence ofperipheral T-cell lymphoma in Sarawak.Current studyanalyzed materialsfrom 1996to 1998,with theaim to elucidatepossiblechangeindiseasepattern, ifany,inSarawak 15yearslater. A totalof70re-confirmedlymphomacaseswereclassifiedusing WHO proposedlistoflymphoidneoplasms. Therewere61(87.1%)non...